NDC 64038-139 - Cyclo/Mag 10mg/200mg
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 64038-139
- Package NDCs from labels
- 64038-139-60
- Manufacturer
- Living Well Pharmacy, Inc. | Apotheca Supply | Spectrum Laboratory Products, Inc.
- Effective date
- 2010-02-17
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| CYCLO/MAG KIT | Living Well Pharmacy, Inc. | Apotheca Supply | Spectrum Laboratory Products, Inc. | 2010-02-17 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 64038-139-60 | Cyclo/Mag 10mg/200mg | 60 g in 1 BOTTLE | POWDER | 60 g | 1 g in 1g | 1 |
DailyMed Dashboard NDC Coverage#
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | DailyMed label | SPL version | Uploaded |
|---|---|---|---|---|---|
| CYCLOBENZAPRINE HYDROCHLORIDE | ACTIVE INGREDIENT | 0VE05JYS2P | CYCLO/MAG 10MG/200MG (CYCLOBENZAPRINE HYDROCHLORIDE, MAGNESIUM OXIDE) KIT [LIVING WELL PHARMACY, INC.] | 1 | |
| MAGNESIUM OXIDE | ACTIVE INGREDIENT | 3A3U0GI71G | CYCLO/MAG 10MG/200MG (CYCLOBENZAPRINE HYDROCHLORIDE, MAGNESIUM OXIDE) KIT [LIVING WELL PHARMACY, INC.] | 1 | |
| CYCLOBENZAPRINE | ACTIVE MOIETY | 69O5WQQ5TI | CYCLO/MAG 10MG/200MG (CYCLOBENZAPRINE HYDROCHLORIDE, MAGNESIUM OXIDE) KIT [LIVING WELL PHARMACY, INC.] | 1 | |
| MAGNESIUM OXIDE | ACTIVE MOIETY | 3A3U0GI71G | CYCLO/MAG 10MG/200MG (CYCLOBENZAPRINE HYDROCHLORIDE, MAGNESIUM OXIDE) KIT [LIVING WELL PHARMACY, INC.] | 1 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Vitranol Fe | FERROUS FUMARATE, FOLIC ACID | PureTek Corporation | b81daf17-430b-6ba2-e053-2a95a90a768b | 2023-01-11 | Warnings, Adverse reactions | 3A3U0GI71G |
| Vitrexate | FOLIC ACID | PureTek Corporation | b34fee43-bea9-45b7-e053-2a95a90aad4d | 2023-01-11 | Warnings, Adverse reactions | 3A3U0GI71G |
| Vitrexate FE | FERROUS FUMARATE, FOLIC ACID | PureTek Corporation | b3637def-a701-673a-e053-2995a90a02d5 | 2023-01-11 | Warnings, Adverse reactions | 3A3U0GI71G |
| Venexa | FOLIC ACID | PureTek Corporation | ba130779-cdfd-086d-e053-2a95a90a2590 | 2023-01-11 | Warnings, Adverse reactions | 3A3U0GI71G |
| Venexa FE | FERROUS FUMARATE, FOLIC ACID | PureTek Corporation | ba142128-21c4-4204-e053-2a95a90ae0d7 | 2023-01-11 | Warnings, Adverse reactions | 3A3U0GI71G |
| Ribotin-E | FERROUS FUMARATE, FOLIC ACID | PureTek Corporation | bb1492c5-bfcd-d632-e053-2a95a90ad7d1 | 2023-01-11 | Warnings, Adverse reactions | 3A3U0GI71G |
| Ventrixyl Fe | FERROUS FUMARATE, FOLIC ACID | PureTek Corporation | c7a626ec-88ec-d899-e053-2a95a90ab0ba | 2023-01-11 | Warnings, Adverse reactions | 3A3U0GI71G |
| Zintrexyl-C | FERROUS FUMARATE, FOLIC ACID | PureTek Corporation | bb1492c5-bfca-d632-e053-2a95a90ad7d1 | 2023-01-11 | Warnings, Adverse reactions | 3A3U0GI71G |
| Cyclobenzaprine hydrochloride | CYCLOBENZAPRINE HYDROCHLORIDE | Unichem Pharmaceuticals (USA), Inc. | 1adcdd8a-30f9-4a7b-853c-948a5589acab | 2023-01-03 | Warnings, Adverse reactions | 0VE05JYS2P |
| CYCLOBENZAPRINE HYDROCHLORIDE | CYCLOBENZAPRINE HYDROCHLORIDE | Asclemed USA, Inc. | 2a6b2ad9-307a-4976-98b7-1b96e0408da7 | 2022-09-14 | Warnings, Adverse reactions | 0VE05JYS2P |
| Cyclobenzaprine Hydrochloride | CYCLOBENZAPRINE HYDROCHLORIDE | Asclemed USA, Inc. | f8dec4e2-3151-4a79-b194-a11a57ada0b6 | 2022-09-03 | Warnings, Adverse reactions | 0VE05JYS2P |
| Cyclobenzaprine Hydrochloride | CYCLOBENZAPRINE HYDROCHLORIDE | Solco Healthcare U.S., LLC | f558863b-ea3f-4e4b-85e9-edb2573e7151 | 2022-08-22 | Warnings, Adverse reactions | 0VE05JYS2P |
| CYCLOBENZAPRINE HYDROCHLORIDE | CYCLOBENZAPRINE HYDROCHLORIDE | Asclemed USA, Inc. | 751f0d33-ceff-40b0-9329-9125f176e06a | 2022-07-29 | Warnings, Adverse reactions | 0VE05JYS2P |
| Magnesia Oxydata | MAGNESIA OXYDATA | Hahnemann Laboratories, INC. | e45bc2b0-72f4-42e1-e053-2995a90a0e66 | 2022-07-21 | 3A3U0GI71G | |
| Cyclobenzaprine hydrochloride | CYCLOBENZAPRINE HYDROCHLORIDE | Asclemed USA, Inc. | 59945ea1-8136-4014-acd9-cdfe6e11e8da | 2022-07-19 | Warnings, Adverse reactions | 0VE05JYS2P |
| Cyclobenzaprine Hydrochloride | CYCLOBENZAPRINE HYDROCHLORIDE | Proficient Rx LP | e3998083-e3db-4052-9b5b-19d7aaa4e658 | 2022-07-01 | Warnings, Adverse reactions | 0VE05JYS2P |
| Cyclobenzaprine Hydrochloride | CYCLOBENZAPRINE HYDROCHLORIDE | Proficient Rx LP | d8112916-28ae-452c-8ec8-a4972e5f549b | 2022-05-02 | Warnings, Adverse reactions | 0VE05JYS2P |
| Cyclobenzaprine Hydrochloride | CYCLOBENZAPRINE HYDROCHLORIDE | Proficient Rx LP | ffd82a69-a64c-4399-8f5d-bddc70cdc3cf | 2022-05-01 | Warnings, Adverse reactions | 0VE05JYS2P |
| Cyclobenzaprine Hydrochloride | CYCLOBENZAPRINE | Proficient Rx LP | ae6de8d8-33c2-40bd-9dd3-782c879a9d8f | 2022-04-01 | Warnings, Adverse reactions | 0VE05JYS2P |
| CYCLOBENZAPRINE HYDROCHLORIDE | CYCLOBENZAPRINE HYDROCHLORIDE | Alembic Pharmaceuticals Inc. | 3cdde96c-9fc9-4698-872a-25c05318ecb5 | 2021-11-19 | Warnings, Adverse reactions | 0VE05JYS2P |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.